Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Norovirus infections increase significantly, with positive test rates reaching 14% - 2Scientists reveal earliest evidence for shifting of Earth’s crust
- 3Watching ‘Home Alone’ with the kids this holiday season? Brace yourself for '6-7.'
- 4Vote In favor of Your Favored Distributed computing Administration
- 5The 15 Most Compelling Books in History
- Book excerpt: "Eat Your Ice Cream" by Ezekiel J. Emanuel, M.D.
- Vote In favor of Your Favored Cereal
- 10 Demonstrated Systems to Develop Your Internet based Business
- Factbox-Weight-loss drug developers line up to tap lucrative market as competition heats up
- Careful Connections: Building Association and Trust
- How to identify animal tracks, burrows and other signs of wildlife in your neighborhood
- 'The Housemaid' movie with Sydney Sweeney and Amanda Seyfried premieres this month. What the stars have said about the psychological thriller.
- Beyond the habitable zone: Exoplanet atmospheres are the next clue to finding life on planets orbiting distant stars
- One dead, six wounded in various crime-related shootings in Israel over the weekend
